New drug combo shows promise for tough blood cancers in early trial
NCT ID NCT05665530
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RICHTER'S SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817, United States
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Centre Léon Bérard
Lyon, 69373 Cedex 08, France
-
City of Hope
Duarte, California, 91010, United States
-
Claude Huriez Hospital
Lille, 59000, France
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Ente Ospedaliero Cantonale (EOC) lstituto Oncologico della Svizzera italiana (IOSl)- Ospedale San Giovanni (ORBV)
Bellinzona, Canton Ticino, 6500, Switzerland
-
Hopital Henri Mondor
Créteil, 94010, France
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola
Bologna, 40138, Italy
-
Institut Curie
Saint-Cloud, 92210, France
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Keimyung_University Dongsan Hospital
Daegu, 42601, South Korea
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Linear Clinical Research Ltd
Perth, Western Australia, 6009, Australia
-
Monash Health
Melbourne, Victoria, 3168, Australia
-
Ospedale Santa Maria delle Croci - AUSL della Romagna
Ravenna, 48121, Italy
-
Pratia MCM Krakow
Krakow, Lesser Poland Voivodeship, 30-727, Poland
-
Samsung Medical Center
Seoul, 06351, South Korea
-
The Leeds Teaching Hospitals NHS Trust, St James University Hospital
Leeds, West Yorkshire, LS9 7TF, United Kingdom
-
Universitatsklinikum Koln, Klinik I fur lnnere Medizin
Cologne, North Rhine-Westphalia, 50937, Germany
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
-
lnje University Busan Paik Hospital
Busan, 47392, South Korea
-
lstituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST
Meldola, FC, 47014, Italy
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.